AlloVir Past Earnings Performance
Past criteria checks 0/6
AlloVir's earnings have been declining at an average annual rate of -35.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 143.3% per year.
Key information
-35.9%
Earnings growth rate
67.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -143.3% |
Return on equity | -130.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04AlloVir EPS misses by $0.28
Nov 10Revenue & Expenses BreakdownBeta
How AlloVir makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -190 | 48 | 133 |
30 Sep 23 | 0 | -169 | 50 | 128 |
30 Jun 23 | 0 | -167 | 50 | 124 |
31 Mar 23 | 0 | -166 | 51 | 121 |
31 Dec 22 | 0 | -169 | 52 | 119 |
30 Sep 22 | 0 | -189 | 55 | 132 |
30 Jun 22 | 0 | -192 | 54 | 135 |
31 Mar 22 | 0 | -185 | 53 | 129 |
31 Dec 21 | 0 | -172 | 49 | 121 |
30 Sep 21 | 0 | -139 | 44 | 96 |
30 Jun 21 | 0 | -117 | 38 | 80 |
31 Mar 21 | 0 | -91 | 29 | 63 |
31 Dec 20 | 0 | -70 | 22 | 50 |
30 Sep 20 | 0 | -53 | 16 | 40 |
30 Jun 20 | 0 | -37 | 12 | 28 |
31 Mar 20 | 0 | -31 | 12 | 22 |
31 Dec 19 | 0 | -24 | 11 | 16 |
31 Dec 18 | 1 | -8 | 3 | 2 |
Quality Earnings: ALVR is currently unprofitable.
Growing Profit Margin: ALVR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALVR is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.
Accelerating Growth: Unable to compare ALVR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ALVR has a negative Return on Equity (-130.62%), as it is currently unprofitable.